In a population of 42 Philadelphia negative myeloproliferative neoplasm patients, all on systemic active treatment, the likelihood of responding to anti-SARS-CoV-2 BNT162b2 vaccine at 2 weeks after the second dose was significantly lower in the ten patients with myelofibrosis compared to the 32 with essential thrombocythemia ( n = 17) and polycythemia vera ( n = 15) grouped together, both in terms of neutralizing anti-SARS-CoV-2 IgG titers and seroprotection rates (32.47 AU/mL vs 217.97 AU/mL, p = 0.003 and 60% vs 93.8%, p = 0.021, respectively). Ruxolitinib, which was the ongoing treatment in five patients with myelofibrosis and three with polycythemia vera, may be implicated in reducing vaccine immunogenicity ( p = 0.076), though large prospective study is needed to address this issue.
【저자키워드】 COVID-19, mRNA vaccine, Ph negative myeloproliferative neoplasms, 【초록키워드】 Treatment, BNT162b2 vaccine, Prospective Study, anti-SARS-CoV-2, BNT162b2, anti-SARS-CoV-2 IgG, Patient, ruxolitinib, Neutralizing, Philadelphia, patients, neoplasm, vaccine immunogenicity, active treatment, polycythemia vera, second dose, Seroprotection rate, polycythemia, IgG titers, significantly lower, myelofibrosis, FIVE, likelihood, essential thrombocythemia, thrombocythemia, reducing, implicated, 【제목키워드】 BNT162b2 vaccine, Patient, Lower,